MINODYL
Clinical safety rating
cautionComprehensive clinical and safety monograph for MINODYL (MINODYL).
Minodronic acid inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, thereby preventing protein prenylation and inducing osteoclast apoptosis.
| Metabolism | Not significantly metabolized; eliminated primarily unchanged via renal excretion. |
| Excretion | Renal: 90-95% (primarily as metabolites, ~5% unchanged); Fecal: <5% |
| Half-life | Terminal elimination half-life: 4-5 hours; clinical context: requires twice-daily dosing for sustained antihypertensive effect. |
| Protein binding | Minimal (approximately 10% bound to plasma proteins) |
| Volume of Distribution | Vd: 0.7-1.2 L/kg; distributes extensively into smooth muscle cells, with minimal binding to plasma proteins. |
| Bioavailability | Oral: approximately 90% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes |
| Duration of Action | Oral: 2-6 hours; intravenous: 2-4 hours |
| Molecular Weight | 284.3 |
5-10 mg orally twice daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | GFR ≥50 mL/min: no adjustment; GFR 30-49 mL/min: 5 mg once daily; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight ≤30 kg: 0.2 mg/kg/day divided twice daily; >30 kg: 5 mg twice daily. |
| Geriatric use | Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity to hypotension. |
| 1st trimester | Contraindicated due to teratogenic effects (cardiovascular and skeletal malformations) observed in animal studies and limited human data. |
| 2nd trimester | Avoid unless no alternative; risk of fetal hypotension and adverse effects on fetal growth. |
| 3rd trimester | Avoid; may cause fetal hypotension, oligohydramnios, and neonatal complications (e.g., hypotension, renal impairment). |
Clinical note
Comprehensive clinical and safety monograph for MINODYL (MINODYL).
| Placental transfer | Crosses placenta readily; detected in fetal plasma at concentrations approximately equal to maternal plasma. |
| Breastfeeding | Excreted into breast milk in low concentrations; potential for adverse effects in nursing infants (e.g., hypotension, electrolyte disturbances). Use with caution, monitoring infant for signs of hypotension and poor feeding. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Minodyl (minoxidil) is pregnancy category C. In first trimester, animal studies show increased fetal resorptions and malformations; no adequate human studies. Second and third trimesters: risk of fetal bradycardia, hypotension, and hypertrichosis following transplacental exposure. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and electrolytes. Fetal monitoring includes ultrasound for growth, amniotic fluid index, and fetal well-being assessments (e.g., non-stress test, biophysical profile) due to risk of placental insufficiency. |
| Fertility Effects | Minoxidil has no known direct effects on fertility. However, uncontrolled hypertension during pregnancy may impair placental perfusion and affect fertility outcomes. |
■ FDA Black Box Warning
Not typically associated with black box warnings; however, severe hypocalcemia and osteonecrosis of the jaw have been reported with bisphosphonates.
| Serious Effects |
Hypersensitivity to minoxidil or any componentPheochromocytoma
| Precautions | Hypocalcemia must be corrected before initiation, Renal impairment (creatinine clearance <35 mL/min), Osteonecrosis of the jaw (especially with dental procedures), Atypical femur fractures, Severe musculoskeletal pain, GI irritation (esophageal ulceration if oral) |
| Food/Dietary | Avoid high-sodium foods and salt substitutes containing potassium chloride, as minoxidil can cause sodium and water retention and potassium disturbance. Grapefruit juice may increase minoxidil absorption; avoid large quantities. No significant interaction with alcohol, but limit intake due to potential blood pressure effects. |
| Clinical Pearls | Minodyl (minoxidil) is a potent direct vasodilator used for refractory hypertension; always co-administer with a diuretic and beta-blocker to prevent reflex tachycardia and fluid retention. Onset of hypertrichosis is 3-6 weeks; this side effect can be used as a compliance marker, especially in female patients. Avoid in patients with pheochromocytoma or acute myocardial infarction. Monitor for pericardial effusion, especially in patients with renal impairment or connective tissue disease. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly as it may cause severe blood pressure rebound. · This medication often causes increased hair growth on the face, arms, and back; this is reversible upon discontinuation. · You will likely need to also take a water pill (diuretic) and a heart rate control medicine (beta-blocker) to prevent side effects. · Report rapid weight gain (>2 lbs/day), shortness of breath, chest pain, or significant swelling of ankles/feet immediately. · Avoid salt substitutes or potassium supplements unless approved by your provider; monitor for irregular heartbeat. · Do not use the topical minoxidil (Rogaine) for hair loss while on this oral medication unless directed, as it may cause excessive hair growth. |
Loading safety data…